Wird geladen...

NPY(1)R-targeted peptide-mediated delivery of a dual PPARα/γ agonist to adipocytes enhances adipogenesis and prevents diabetes progression

OBJECTIVE: PPARα/γ dual agonists have been in clinical development for the treatment of metabolic diseases including type 2 diabetes and dyslipidemia. However, severe adverse side effects led to complications in clinical trials. As most of the beneficial effects rely on the compound activity in adip...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Metab
Hauptverfasser: Wittrisch, Stefanie, Klöting, Nora, Mörl, Karin, Chakaroun, Rima, Blüher, Matthias, Beck-Sickinger, Annette G.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2019
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6931124/
https://ncbi.nlm.nih.gov/pubmed/31918918
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molmet.2019.11.009
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!